

THE LINDE GROUP (BOC LIMITED) TO DISTRIBUTE MUTE AND TURBINE

KEY HIGHLIGHTS:

- **Rhinomed and The Linde Group and its Australian subsidiary, BOC Limited, have entered into a supply agreement for the distribution of Mute and Turbine into Australia and New Zealand.**
- **BOC will take on logistics and distribute to Australian and New Zealand based pharmacies, sleep clinics, hospitals, convenience stores and medical practices.**
- **The agreement delivers significant scale for Mute/Turbine in the Australian and New Zealand markets.**
- **The Linde Group are global leaders in the US\$10 Billion Sleep apnea market.**
- **Revenues to flow second half of FY 2016/17.**

7th December, 2016. Melbourne, Australia.

Rhinomed (ASX:RNO), the Australian respiratory technology company announced it has entered into a distribution and supply agreement with The Linde Group and its Australian subsidiary BOC Limited.

BOC will manage logistics and distribute Rhinomed's breathing technologies, Mute and Turbine, in the Australian and New Zealand markets.

Rhinomed will ship product directly from its Hong Kong warehouse to BOC's logistics centre in Sydney. Under the arrangement, BOC will fulfill and supply all of Rhinomed's existing contracts within Australia - covering the existing 700 pharmacies currently stocking the product.

BOC brings an extensive and highly experienced sales force to support the growing uptake of Rhinomed's products in the region. Mute complement's BOC's current sleep equipment offering that includes CPAP masks and supplies and in-home sleep studies, by providing an affordable, easy-to-use product for assisting with night-time nasal congestion and snoring.

Mr Colin Smith, Head of Healthcare, BOC Limited commented: "BOC is proud to partner with Rhinomed as their distributor for Mute and Turbine across Australia and New Zealand. As a leader in the Australian and New Zealand sleep markets BOC has been providing quality sleep therapy to patients in Australia for more than ten years."

RHINOMED

MAKE EVERY BREATH COUNT

BOC Limited is part of The Linde Group, the global gas, healthcare and engineering company, operating in over 70 countries with an annual turnover of more than €17 Billion. BOC provides pharmaceutical and medical products and services across hospitals, clinics, intermediate care centres, aged care facilities, GPs, emergency centres, convenience stores, service stations and patients' homes. The Linde Group operates in the US through its subsidiary Lincare, one of the largest suppliers of CPAP and sleep services in the USA. Lincare provides services and equipment, operating from approximately 1,000 locations in 48 U.S. states and Canada.

“The relationship with The Linde Group and its subsidiary BOC further cements Rhinomed’s strategy of positioning Mute as the front-line solution for millions of people as they enter the sleep solutions market. This agreement will deliver significant scale to Mute’s presence in the Australian and New Zealand sleep market.” commented Rhinomed CEO Michael Johnson

Mute is a nasal stent designed to hold open and individually dilate the nasal airway, alleviating the effect of nasal obstruction, to improve nasal breathing and reduce snoring. It is currently available in leading pharmacy and sleep clinics in the US, Canada, the UK and Australia, as well as via online platforms.

Snoring is increasingly recognised as the first touch point for millions of people as they begin their journey into diagnosing a range of sleep disrupted breathing issues. The relationship with BOC and The Linde Group enables Rhinomed to further advance opportunities in this growing market and positions Mute as the go-to starting point in the sleep journey.

Media Enquiries

Michael Johnson, CEO & Managing Director

+61 (03) 8416 0900

mjohnson@rhinomed.global

Follow us on

Twitter @rhinomedceo and @mutesnoring and @theturbinecom

About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.

About BOC Limited

BOC has been providing quality sleep therapy to patients in Australia for over ten years. As part of the Linde Group, we have extensive global and local experience treating patients with sleep disorders such as obstructive sleep apnoea. We offer the latest Continuous Positive Airway Pressure (CPAP) equipment and expert support to improve our patients' sleep, prevent snoring and help them feel more energetic during the day.